文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-FDG PET作为结直肠肝转移消融治疗后疾病进展的新型影像生物标志物

18F-FDG PET as novel imaging biomarker for disease progression after ablation therapy in colorectal liver metastases.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-02-08

本回顾性研究纳入54例共90个病灶的结直肠肝转移患者,分析消融前基线18F-FDG PET/CT代谢参数与复发的关系。多变量分析显示,校正病灶大小和手术方式后,代谢参数与局部肿瘤无进展生存或肝外无复发生存无关;但较低的SULpeak、SULmax、SULmean和cSULmean与显著更好的新肝内无复发生存相关,且独立于病灶大小、数目和既往化疗。

要点

  • 消融前18F-FDG PET/CT代谢参数与局部肿瘤无进展生存无关。
  • 较低SULpeak、SULmax、SULmean和cSULmean与显著更好的新肝内无复发生存相关。
  • 经皮穿刺方式与更短的局部肿瘤无进展生存显著相关。

核心结论

  • 消融前18F-FDG PET/CT代谢参数与局部肿瘤无进展生存无关,但低代谢参数值与显著更好的新肝内无复发生存相关。
  • 作者认为这些发现的临床意义可能在于识别最可能从辅助或联合治疗策略中获益的高危患者。

研究设计与样本

  • 回顾性研究,纳入所有连续接受经皮或开放热消融治疗且治疗前有基线18F-FDG PET/CT的结直肠肝转移患者。
  • 共纳入54例患者、90个病灶。
  • 采用多变量Cox回归进行生存分析,使用不同模型分析代谢参数(SULpeak、SULmean、SULmax、部分容积校正的SULmean(cSULmean)和总病灶糖酵解(TLG)),并校正肿瘤和手术特征。
  • 研究终点为局部肿瘤无进展生存(LTP-FS)、新肝内无复发生存(NHR-FS)和肝外无复发生存(EHR-FS)。
  • 临床和影像随访数据作为参考标准。

主要发现

  • 单变量Cox回归分析产生八个模型。
  • 多变量分析显示,校正病灶大小和手术方式后,没有任何代谢参数与LTP-FS或EHR-FS相关。
  • 经皮穿刺方式与更短的LTP-FS显著相关。
  • 较低SULpeak、SULmax、SULmean和cSULmean值与显著更好的NHR-FS相关,且独立于病灶大小、数目和既往化疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Recurrent disease following thermal ablation therapy is a frequently reported problem. Preoperative identification of patients with high risk of recurrent disease might enable individualized treatment based on patients' risk profile. The aim of the present work was to investigate the role of metabolic parameters derived from the pre-ablation 18F-FDG PET/CT as imaging biomarkers for recurrent disease in patients with colorectal liver metastases (CLM). METHODS: Included in this retrospective study were all consecutive patients with CLM treated with percutaneous or open thermal ablation therapy who had a pre-treatment baseline 18F-FDG PET/CT available. Multivariable cox regression for survival analysis was performed using different models for the metabolic parameters (SULpeak, SULmean, SULmax, partial volume corrected SULmean (cSULmean), and total lesion glycolysis (TLG)) corrected for tumour and procedure characteristics. The study endpoints were defined as local tumour progression free survival (LTP-FS), new intrahepatic recurrence free survival (NHR-FS) and extrahepatic recurrence free survival (EHR-FS). Clinical and imaging follow-up data was used as the reference standard. RESULTS: Fifty-four patients with 90 lesions were selected. Univariable cox regression analysis resulted in eight models. Multivariable analysis revealed that after adjusting for lesion size and the approach of the procedure, none of the metabolic parameters were associated with LTP-FS or EHR-FS. Percutaneous approach was significantly associated with a shorter LTP-FS. It was demonstrated that lower values of SULpeak, SULmax, SULmean , and cSULmean are associated with a significant better NHR-FS, independent of the lesion size and number and prior chemotherapy. CONCLUSION: We found no association between the metabolic parameters on pre-ablation 18F-FDG PET/CT and the LTP-FS. However, low values of the metabolic parameters were significantly associated with improved NHR-FS. The clinical implication of these findings might be the identification of high-risk patients who might benefit most from adjuvant or combined treatment strategies.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Samim M, Prevoo W, de Wit-van der Veen BJ, et al. 18F-FDG PET as novel imaging biomarker for disease progression after ablation therapy in colorectal liver metastases. Eur J Nucl Med Mol Imaging. 2017. PMID: 28180965. doi:10.1007/s00259-017-3637-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。